Spero Therapeutics, Inc.

Healthcare

NASDAQ:SPRO · NASDAQ Global Select

Market Cap $156.33M Beta 1.46 P/E (TTM) 10.7

$2.85 +5.56%

+$0.15 today

52W Low $1.80High $3.22

Vol 0.62M · Avg 0.56M

EPS (TTM)$0.27

Biotechnology

Filings

Ground the analysis in primary documents

Pair price history with recent company filings so you can connect market moves to the actual disclosures behind the business.

Price History

Dividend-adjusted closing price

Events

Change

+0.71%

Period High

$3.04

Period Low

$1.83

Latest

$2.85

SEC Filings

Recent regulatory filings

No filings found.

Competitors

Peer companies in the same sector

Health

Opus Genetics, Inc.

NASDAQ:IRD

$328.84M

TuHURA Biosciences, Inc.

NASDAQ:HURA

$147.74M

Acumen Pharmaceuticals, Inc.

NASDAQ:ABOS

$143.56M

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

$102.67M

Seer, Inc.

NASDAQ:SEER

$94.57M

Cognition Therapeutics, Inc.

NASDAQ:CGTX

$89.03M

Inovio Pharmaceuticals, Inc.

NASDAQ:INO

$58.95M

Seres Therapeutics, Inc.

NASDAQ:MCRB

$55.20M

Actuate Therapeutics Inc

ACTU

$48.33M

VistaGen Therapeutics, Inc.

VTGN

$18.88M

What is the latest SPRO filing?

The latest filing shown is 8-K dated May 13, 2026.

How many recent filings does SPRO have?

Intrinsic Alpha currently shows 20 recent filings for SPRO.

Explore More

Continue the stock analysis

Jump to another research area for this company.

OverviewStart with valuation, alerts, peers, and the full company snapshot.DCFAdjust assumptions and compare intrinsic value against the market price.FinancialsReview income statement, balance sheet, and cash flow trends.HealthCheck liquidity, leverage, and balance sheet strength.GrowthCompare historical growth, cash generation, targets, and peers.DividendsInspect dividend history, payout durability, and shareholder returns.ManagementReview leadership context, insider activity, and capital efficiency.